Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early conversion from calcineurin inhibitors to Rapamune (sirolimus) in kidney transplant recipients with impaired renal function
2004-004884-31Phase 4Completed
- Sponsor
- Newcastle Hospitals NHS Foundation Trust
- Start
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of sirolimus in chronic kidney disease (CKD) and Kidney allograft dysfunction (2 arms), sponsored by Newcastle Hospitals NHS Foundation Trust. Primary endpoints: Renal function (creatinine clearance/GFR) and Serum creatinine change. Started Oct 2007; status: completed.
02
Drugs
sirolimus
03
Conditions
chronic kidney disease (CKD)Kidney allograft dysfunction
Beyond the preview
Go deeper on 2004-004884-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004884-31.